I-O

IO Biotech is a clinical-stage biopharmaceutical company focused on developing "off-the-shelf" immune-modulating cancer vaccines using its proprietary T-win platform. This technology activates naturally occurring T cells to target both tumor cells and immunosuppressive cells in the tumor microenvironment that express specific proteins such as IDO and PD-L1. The company's lead candidate, IO102-IO103, is currently in a pivotal Phase 3 clinical trial in combination with pembrolizumab for the first-line treatment of advanced melanoma. Additionally, IO Biotech is evaluating this candidate in Phase 2 basket trials for several other solid tumors, including lung and head and neck cancers. Headquartered in Copenhagen, Denmark, the company is listed on the Nasdaq and is advancing a pipeline that includes targets like Arginase 1 and TGF-beta.